Published in final edited form as:

J Neuroimmune Pharmacol. 2019 March ; 14(1): 33–43. doi:10.1007/s11481-018-9795-4.

Host and Viral Factors Influencing Interplay between the Macrophage and HIV-1

Viviane Machado Andrade¹, Mario Stevenson²

Mario Stevenson: MStevenson@med.miami.edu

¹Molecular Cell and Developmental Biology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA

²Division of Infectious Diseases, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA

Abstract

HIV-1 persists in cellular reservoirs that cannot be eliminated by antiretroviral therapy (ART). The major reservoir in infected individuals on effective ART is composed of resting memory CD4⁺ T cells that harbor proviral cDNA, and undergo a state of latency in which viral gene expression is minimal to absent. The CD4⁺ T cell reservoir has been extensively characterized. However, other HIV-1-permissive cells may contribute to HIV-1 persistence. Lentiviruses have a long recognized association with macrophages. However, the role, if any, played by macrophages in HIV-1 persistence is not well understood. Macrophages are resistant to cell death upon HIV-1 infection, and can survive for long periods of time, making them ideal host cells in which the virus might persist. Studying macrophages is challenging, as these cells reside in nearly all tissues. Moreover, detecting viral DNA or RNA in macrophages does not necessarily indicate that these cells will produce replication-competent viral particles. Currently, the gold standard assay to detect cellular reservoirs is the ex vivo quantitative viral outgrowth assay (QVOA), which requires a patient blood draw. However, macrophages reside deep within tissues that are inaccessible in living subjects, such as the central nervous system (CNS). Therefore, tools other than QVOA must be developed to identify cellular reservoirs that reside in the tissues. In this review, we will focus on the main aspects involved in HIV-1 persistence, including the molecular mechanisms of viral evasion, the main cell types responsible for harboring persistent HIV-1 and the tissue compartments that are likely to be reservoirs for HIV-1.

Keywords

Macrophages; Persistence; CNS; Reservoir; HIV-1 infection

Viviane Machado Andrade, vxm147@med.miami.edu.

Conflict of Interest The authors declare that they have no conflict of interest.

Introduction

The first weeks of HIV-1 infection, defined as the acute phase, is characterized by an exponential rise in viral load, rapid loss of CD4+ T cells, immune activation and symptoms such as headaches and fever. These conditions are ideal for explosive viral growth, which drives reservoir establishment very early after initial HIV-1 infection. However, the sooner an HIV-1-infected individual starts treatment with ART, the smaller the size of the reservoir, as seen by a delayed rebound when ART is interrupted (Li et al. 2016; Henrich et al. 2017).

HIV-1 infects two major cell types: CD4+ T cells (Barre-Sinoussi et al. 1983; Lifson et al. 1986; Maddon et al. 1986) and macrophages (Koenig et al. 1986). In terms of understanding viral persistence, most of the attention has focused on the resting memory CD4+ T cells; these cells are long-lived and harbor an integrated copy of HIV-1 cDNA. However, the size of HIV-1 reservoir in these cells is very small. Viral outgrowth assays have shown that approximately 1 in one million resting memory CD4+ T cells harbor replication-competent proviral HIV-1 DNA (Eriksson et al. 2013). From the total copies of proviral DNA that is detectable in resting memory CD4+ T cells, this small reservoir accounts for nearly 1% of the number of HIV-1 proviral DNA that is able to support the production of replication-competent virus. Moreover, this may not be the only reservoir responsible for sustaining persistent HIV-1. HIV-1 variants isolated at rebound viremia from ART-suppressed individuals, showed a considerable genetic discordance from plasma rebound HIV-1 compared to cell-associated RNA and replication-competent viruses found in latently infected memory CD4+ T cells prior to ART discontinuation (Chun et al. 2000). Although this study was performed in the 2000's, these cells are the only characterized reservoir for HIV-1.

In addition to CD4+ T-cells, macrophages are also permissive to infection by HIV-1 (Koenig et al. 1986). These cells are readily infected upon HIV-1 transmission, and do not show apparent signs of cytotoxicity following HIV-1 infection (Swingler et al. 2007; Coiras et al. 2009). Macrophages can be infected by HIV-1 and sustain a linear, steady HIV-1 production without undergoing cell death (Aquaro et al. 2002). Altogether, these features harbored by macrophages could likely contribute to viral persistence of the infected cell.

There is some debate regarding the mechanisms involved in reservoir maintenance. The prevailing view is that the reservoir is maintained by the intrinsic stability of the latently infected memory CD4+ T cell (Siliciano et al. 2003; Crooks et al. 2015). More recently, it has been shown that latently infected cells can undergo mitosis, which results in duplication of the latently infected cell (Chomont et al. 2009). While it was originally believed that this process predominantly leads to duplication of defective proviruses, it now appears that competent proviruses can be duplicated and serve as a template for the production of infectious viruses (Simonetti et al. 2016; Hosmane et al. 2017). It has also been shown that ART does not effectively penetrate all tissues to equal levels and that suboptimal drug concentrations might provide conditions for de novo infection (Fletcher et al. 2014). As a consequence, HIV-1-infected cells may not be completely eliminated by ART and may undergo a steady, "topping up" by homeostatic duplication and perhaps by generation of newly infected cells. HIV-1 replication in macrophages is also more resistant to inhibition by

nucleoside analogue reverse transcriptase inhibitors (NRTI), as these require a phosphorylation step in order to become active, and phosphorylation activity in macrophages is reduced, compared to CD4⁺ T cells (Perno et al. 2006). In this review, we will examine the role of distinct types of macrophages in the context of HIV; the mechanisms imposed by the cellular immune response to eliminate the virus from infected cells, and will discuss the mechanisms by which macrophages may be potential candidates for HIV-1 persistence, including the most recent evidence supporting this hypothesis.

The Dynamics of HIV-1 Reservoir Maintenance and its Establishment in the Acute Phase

The first and only patient cured from HIV-1 reported to date, is Timothy Brown, known as the Berlin patient (Hutter et al. 2009). This patient developed acute myeloid leukemia after infection by HIV-1. He subsequently underwent 2 rounds of allogeneic hematopoietic stem cell transplantation (HSCT) with cells containing a homozygous $\Delta 32$ mutation in the gene encoding for CCR5, which conferred resistance to HIV-1 infection. The transplanted, new immune system replaced the old immune cells completely, and this patient remains in remission for over 8 years since he stopped ART (Hutter et al. 2009). The Berlin Patient has galvanized efforts amongst researchers to pursue a cure for HIV/AIDS using elements that led to the cure of Timothy Brown. As such, this remains an intense area of investigation. Some approaches have focused on early treatment initiation as a way to limit reservoir size and thereby make the task of eliminating the reservoir less challenging. Li and colleagues have shown that the earlier an HIV-1-infected individual starts treatment, the smaller is the size of the reservoir. Therefore, individuals who initiated ART during acute HIV-1 infection, exhibited delayed virus rebound following treatment interruption, and this was associated with low levels of cell associated-RNA (CA-RNA) present pre-ATI. However, those with higher pre-ATI CA-RNA, showed shorter time of rebound and had significantly higher levels of residual viremia pre-ATI (Li et al. 2016).

Another recent study evaluated whether initiating ART extremely early during acute HIV-1 infection would prevent HIV-1 from establishing a reservoir and ultimately prevents rebound. The study involved two HIV-1 infected patients who were on pre-exposure prophylaxis (PreP) program after 10–12 days post-infection (Henrich et al. 2017). Patient A had very low plasma viremia before ART initiation. The participant achieved undetectable viral load, and after extensively sampling failed to detect HIV-1 from several distinct tissue sites over the course of 2 years, ART was stopped. However, 7.4 months later, HIV-1 rebounded. This case resembles the case of one of the Boston patients (patient B), who underwent allogeneic bone-marrow transplantation, followed by 3 years on ART (Henrich et al. 2014). Upon treatment interruption, the patient remained on remission for 8 months prior to HIV-1 rebound. These two cases suggest that, although preventive measures were taken to reduce viral reservoir size to undetectable levels, ultimately, HIV-1 still persisted. This has taught us that the inability to detect HIV-1 does not mean it is not there.

Overview of Lentivirus Infection in Macrophages

Infection of a cell first requires interaction of the viral envelope glycoprotein with CD4, which is the primary receptor for HIV-1. A conformational change in the viral envelope that is created by CD4 interaction then exposes co-receptor binding epitopes on the viral envelope. While infection of CD4⁺ T cells is readily achieved by HIV-1, CD4 expression on macrophages is very low - barely detectable by FACS – such that viruses capable of infecting macrophages require an envelope with a high affinity for CD4. This is the primary determinant of macrophage tropism (Kumar et al. 2014). Initial infection is initiated by so-called transmitted/founder (T/F) variants. These viruses usually infect cells expressing high levels of the CD4 receptor on the cell surface but are unable to infect macrophages (Salazar-Gonzalez et al. 2009). Therefore, during the course of infection, HIV-1 must undergo changes in envelope that confers high CD4 affinity and macrophage tropism. However, the mechanisms by which HIV-1 has evolved to efficiently infect these cells remain unclear. The rapid depletion of CD4⁺ T cells in the acute phase of infection may favor the appearance of genetic HIV-1 variants that undergo evolutionary pressure to infect other cell types. However, upon early ART initiation, T/F HIV-1 strains may not undergo enough genetic diversification to allow for rapid evolution and subsequent appearance of macrophage-tropic variants.

Macrophages are cells of the innate immune system that serve as scavengers to eliminate cells infected by pathogens. Macrophages are found in tissues, and are responsible for protecting these sites from infection. Therefore, they can be found in nearly every tissue in the body and may have distinct functions depending on their location. For instance, the expression of key receptors necessary for HIV-1 infection may vary according to the site where the macrophage reside in, which determines the susceptibility to HIV-1 among different macrophage phenotypes. Shen and colleagues demonstrated that vaginal macrophages, in comparison to gut macrophages, are more susceptible to HIV-1 infection and are able to sustain HIV-1 replication, as they express the key receptors for HIV-1 entry including CD4 and CCR5 (Shen et al. 2009). In other tissues, the presence of HIV-1 DNA and RNA has been detected in alveolar macrophages of HIV-1-infected individuals on effective ART, suggesting the potential of these cells to harbor persistent virus (Jambo et al. 2014; Cribbs et al. 2015). Moreover, alveolar macrophages harboring proviral HIV-1 DNA have been associated with a reduced phagocytic activity, leading to a higher risk of acquiring respiratory infections.

Although less studied, Kupffer cells, the resident tissue macrophage in the liver, have been also reported to undergo infection by HIV-1 (Schmitt et al. 1990; Hufert et al. 1993; Mosoian et al. 2017). An early study analyzed 7 *post-mortem* liver tissues of patients who developed AIDS. HIV-1 DNA was found in the liver, as well as in peripheral blood monocytes in 3 out of 7 patients analyzed (Hufert et al. 1993). More recently, a study demonstrated that when Kupffer cells are cultured *ex-vivo*, followed by exposure to HIV-1, these cells become productively infected. They have also shown an enhancement of CD14 and TLR4 expression in these cells (Mosoian et al. 2017), thereby promoting proinflammatory responses that may impact negatively the immune response to fight against hepatic inflammation and bacterial translocation.

The least studied type of macrophages, but perhaps the most important in terms of HIV-1 pathogenesis, are the brain macrophages, including the microglia and perivascular macrophages. Infection of these cells is associated with HIV-1 pathogenesis and its complications throughout the course of HIV-1 infection and development into AIDS. However, in HIV-1-infected individuals, there are very limited studies associating the HIV-1 reservoir to human microglia, as this tissue is not readily accessible in vivo. Some early studies from the 80's have demonstrated the presence of HIV-1 infection in the CNS, and these studies suggested the presence of HIV-1 in myeloid cells in the brain. HIV-1 was detected in post-mortem brain tissue of individuals who have developed AIDS by in-situ hybridization, mainly in the white matter, and restricted to endothelial capillaries, mononuclear inflammatory cells and giant cells (Wiley et al. 1986). Another study performed in sections of the brain, demonstrated the presence of HIV-1 (formally HTLV-III) in cells that resembled monocyte/macrophages, and were localized in the cortex of the frontal, temporal, and parietal lobes (Gabuzda et al. 1986). Another study demonstrated the presence of mononucleated and multinucleated macrophages that were actively producing viral RNA and viral particles in the brain of AIDS patients (Koenig et al. 1986). Although these studies demonstrated that myeloid cells in the brain are able to support HIV-1 infection, it is unclear whether these cells harbor persistent HIV-1 in patients on suppressive ART that could generate productive viral particles once ART is interrupted. More recently, studies have demonstrated the presence of infected microglia and peripheral macrophages in the brain of HIV-1-infected individuals on suppressive ART. Post-mortem brain biopsies of two individuals on effective ART were assessed for the presence of viral RNA, total and integrated HIV-1 DNA, which were readily detected (Asahchop et al. 2017). In this same study, they found that concentration of several antiretroviral drugs was substantially reduced in different regions of the brain, which may contribute to viral persistence, even in individuals on suppressive ART.

Despite the inaccessibility of this tissue, HIV-1 has been found in microglia and perivascular macrophages in the CNS of HIV-1-infected adults from adult cultured temporal lobe tissue (Albright et al. 2000) and from brain autopsy tissue in infants (Ioannidis et al. 1995). Other studies have taken advantage of studying the cerebrospinal fluid (CSF) to predict the dynamics of HIV-1 infection in the brain (Schnell et al. 2011). Despite efforts to reach out to this tissue, the CNS remains one of the least studied sites in the body, due to the difficulty in accessing tissue sites. Therefore, it remains unclear whether the CNS, including microglia, is a truly reservoir for HIV-1.

Macrophages not only play an important role in HIV-1 infection, but also are critical in the context of lentiviral infections across several other animal species. These cells are permissive to a wide range of lentiviral infections. In goats, the caprine arthritis-encephalitis virus (CAEV) infects blood-derived caprine monocytes, with increased infectivity when differentiating into macrophages (Anderson et al. 1983). The infection of caprine macrophages by CAEV is also suggested to play a role in viral persistence in these cells. Another lentivirus found in sheep, the visna virus is characterized by a slow disease progression, and long periods of incubation (Narayan 1983). Early studies have shown that the visna virus infects macrophages in the lung, as observed by the presence of viral RNA in these cells. However, the presence of RNA was not correlated with viral replication. The

study found macrophage precursor cells in the bone marrow harboring replicate-competent visna virus, suggesting a reservoir of latently infected cells (Gendelman et al. 1985).

The CNS as a Reservoir for HIV-1

Most of the information regarding the association of HIV-1 with the CNS has been derived from a plethora of pathologic, immune, behavioral and virologic studies (Moskowitz et al. 1984; Levy et al. 1986). These studies have shown that the CNS is susceptible to infection in immune-compromised HIV-1 individuals. Infection of microglia in the CNS is also believed to underscore HIV-1 neuropathogenicity (Persidsky and Poluektova 2006; Wachter et al. 2016). In SIV/macaque model, brain macrophages and microglia are also permissive to infection (Micci et al. 2014). Prior to the advent of ART, the incidence of HIV-associated dementia (HAD) was over 50% in HIV-1-infected individuals. However, even after ART era, there have been several cases of neurocognitive impairment that vary in severity among ART-treated individuals (Antinori et al. 2007). Of the individuals on ART, a considerably percentage of HIV-1-infected subjects still manifests neurological symptoms, that associated with an increase in makers for neuronal inflammation and a decrease in a marker for neuronal integrity (Harezlak et al. 2011). HIV-1 is a neurotropic virus that is believed to cross the blood brain barrier (BBB) through a mechanism known as “Trojan horse” (Kramer-Hammerle et al. 2005). Circulating cell-free virus, and HIV-1 infected monocytes and CD4+ T cells are recruited to the CNS through cytokine secretion by brain endothelial cells upon the presence of viral proteins (Fig. 1) (Albright et al. 2003). Infected cells and free-cell virus cross the BBB through transcytosis of the endothelial cells, into the brain. Cell-free viruses also cross the BBB through damaged tight junctions, to further infect astrocytes and microglia. Infection of cells in the CNS leads to a cascade of events, with release of proinflammatory cytokines as IL-1 β , TNF- α , and HIV-1 viral proteins Tat and gp120 (Fig. 1), which contribute to neuronal dysfunction (Li et al. 2011; Mamik et al. 2011). HIV-1-infected individuals may consequently experience cognitive, behavioral, and motor dysfunction due to consequences of HIV-1-associated CNS damage. This series of cyclical events leads to loss of pericytes, which are supportive cells of the endothelial vasculature. *Post-mortem* analysis of the brain of HAD subjects show that an increased number of monocytes are found in the perivascular space of the CNS (Fischer-Smith et al. 2001). In a mouse model, monocytes exposed to proinflammatory molecules, such as LPS and TNF- α , and IL-10, exhibited greater CNS migration, as compared to non-activated monocytes (Persidsky et al. 1997). This likely contributes to the replenishment of perivascular macrophages, which could in turn contribute to an expansion of the HIV-1 reservoir in the CNS.

Infected cells, primarily monocytes, are recruited to the CNS site through cytokine secretion by the brain endothelial cells in the presence of viral HIV-1 proteins. HIV-1 is then released into the CNS to further infect microglia and perivascular macrophages. Infection of brain myeloid cells further stimulates cytokine production by infected microglia and macrophages *in trans*. IL-1 β , TNF- α and the HIV-1 proteins gp120 and Tat activates the brain barrier endothelial cells and pericytes, leading to inflammation and increased expression of tight junction molecules. This series of events leads to decreased pericyte function, which may

induce changes in BBB permeability, to allow the recruitment of additional infected monocytes and cell-free viruses to the CNS.

Because the BBB is a highly controlled barrier to protect the CNS, some antiretroviral drugs may access CNS tissues at sub-optimal concentrations, which may further undermine HIV-1 control in microglia and perivascular macrophages. Since myeloid-derived cells are the main cell population infected by HIV-1 in the brain, and since the CNS may serve as a drug sanctuary for HIV-1, this may create conditions for viral persistence. This is even more evident considering that different levels of HAD can be manifested in ART-treated patients, indicating that brain damage still occurs, despite antiretroviral treatment.

Obstacles to Studying HIV-1 Persistence in Macrophages

The study of HIV-1 in human macrophages from living subjects is a daunting experimental undertaking. Macrophages reside in nearly all tissues in the human body, some which are inaccessible in living subjects. There is the issue of sampling in that a biopsy of lymph nodes may not be representative of what is happening in specialized macrophages in other tissues. In addition, some tissues are inaccessible in living subjects. This includes the CNS, which is one of the most important sites in terms of HIV-1 infection of macrophages. As mentioned above, studies from the SIV/macaque and humanized models predict that microglia and perivascular macrophages are likely to be infected by HIV-1, which could contribute to HIV-1 persistence.

It has been argued that the presence of SIV DNA in macrophages from SIV-infected macaques may be from a phagocytized T cell rather than through active infection of macrophages (Calantone et al. 2014). However, phagocytosis of infected CD4+ T cells could represent a novel mechanism for myeloid cell infection (Baxter et al. 2014). Furthermore, in the SIV/macaque model, macrophage infection is not observed with viral variants that have envelopes that are strictly T cell tropic (Bannert et al. 2000). In other words, T cell phagocytosis of infected CD4+ T cells may occur but appears to be rare.

Virus-Host Interplay: The Cell Mediated Immune Response to HIV-1 Vs the Efforts of HIV-1 to Evade it.

During the course of infection, HIV-1 overcomes the effects of the immune system through viral proteins that target cellular responses against the virus. Once infected, macrophages release inflammatory cytokines and chemokines that recruit other cells of the innate and adaptive immune system (Xing et al. 2009; Ben Haij et al. 2015). Although the innate immune system efficiently mounts an antiviral response against HIV-1, viral proteins are able to overcome the antiviral effects of the immune system through several mechanisms. The HIV-1 accessory proteins play a central role in the viruses evasion of host antiviral immunity.

A common feature amongst different pathogens is their ability to evade the host's immune response by down regulating major histocompatibility complex molecules (MHCs), thereby preventing recognition by cytotoxic T lymphocytes (CTLs). The accessory protein,

negative factor (Nef), down regulates MHC-1, which prevents macrophages and T lymphocytes from presenting HIV-1 antigens to CD8+ T cells. There are two proposed models by which Nef downregulates MHC-1 (Fig. 2); the first is by binding to MHC-1 in the endoplasmic reticulum (Atkins et al. 2008; Dikeakos et al. 2010), followed by migration to the *trans-golgi* network (TGN) (Fig. 2A). Nef-MHC-1 complex is then phosphorylated, preventing trafficking to the cell membrane and consequently transported to lysosome for degradation (Kasper et al. 2005). The second is through increasing endocytosis of cellular MHC-1, by transporting into endosomes followed by lysosomal degradation (Fig. 2B) (Atkins et al. 2008).

Nef downregulates MHC-1 on the cell surface thereby preventing antigen presentation to cytotoxic CD8+ T cells. There are two proposed mechanisms by which Nef disrupts MHC-1. (A) The first is by binding of Nef to MHC-1 in the endoplasmic reticulum, followed by migration to the *trans*-Golgi network (TGN). Upon MHC-1 phosphorylation, Nef-MHC-1 complex is diverted from the TGN and sequestered to lysosomal compartments, where MHC-1 will be degraded. (B) The second mechanism, by which Nef downregulates MHC-1, is through increased endocytosis of cellular MHC-1, followed by lysosomal degradation.

Another function attributed to Nef, in association with the viral protein Vpu, is the downregulation of an important receptor associated with leukocyte turnover, L-selectin (CD62L) leukocyte homing receptor. CD62L is associated with cell transcytosis on the vascular endothelium of peripheral lymph nodes. Upon infection of primary CD4+ T cells, levels of CD62L on the cell surface are reduced due to sequestering of CD62L in perinuclear compartments, triggered by Nef and Vpu (Vassena et al. 2015). By blocking CD62L functions, leukocytes are prevented from eliminating pathogens, allowing HIV-1 to evade the host immune response.

In addition to cell-mediated immunity, there are host proteins that potently antagonize HIV-1 infection and here too, the viral accessory proteins play a key role in circumventing these obstacles. SAM domain and HD domain-containing protein 1 (SAMHD1) reduces dNTP concentrations in non-mitotic cells such as macrophages where dNTPs are excessive to need. Since dNTPs are also required for reverse transcription of viral DNA, infection of macrophages is limited in the presence of SAMHD1. For HIV-2 and SIV, the situation is clear. The viral Vpx protein interacts with SAMHD1 and targets it for proteasomal destruction thereby raising dNTP concentrations to levels conducive to efficient reverse transcription. However, HIV-1 does not harbor a Vpx protein and the related Vpr protein does not appear to harbor a Vpx-like activity (Sharova et al. 2008). Some studies suggest that HIV-1 has evolved a reverse transcriptase that can polymerize in low dNTP environments (Lenzi et al. 2015; Nguyen et al. 2015). Furthermore, some studies have proposed that macrophages in G1-like stage have reduced levels of SAMHD1 (Kyei et al. 2015; Milcochova et al. 2017). When macrophages enter a G1-like stage, cycling-dependent kinases (CDKs) phosphorylate SAMHD1, reducing its activity. Collectively, this suggests that HIV-1 has been hard pressed to come up with a way to avoid SAMHD1 restriction and argues that infection of macrophages might serve an important role in virus-host interplay.

Macrophages are also resistant to cell killing by CD8⁺ T lymphocytes. In a study using a SIV/macaque model, SIV-specific CD8⁺ T cells were freshly sorted and co-cultured ex-vivo with SIV-infected autologous CD4⁺ T cells or monocyte-derived macrophages from naïve macaques. The study found that viral replication was suppressed in infected CD4⁺ T cells, whereas CTLs failed to eliminate infected macrophages (Vojnov et al. 2012; Rainho et al. 2015). This study suggests that macrophages are resistant to CD8⁺ T cell killing in primate models, and therefore may be contributing to viral persistence in primates.

Why would Macrophages Be a Suitable Candidate for a Viral Reservoir?

There are several lines of evidence supporting the notion that macrophages are reservoir for HIV-1. However, for a cell to be considered reservoir, it must harbor a proviral DNA that upon reactivation, is capable of generating replication competent viruses. There have been studies in animal models showing that macrophages are a viral reservoir (Arainga et al. 2017; Avalos et al. 2017; Honeycutt et al. 2017). However, the same conclusion cannot be made for those HIV-1-infected individuals suppressed by ART.

Perhaps the first major evidence that macrophages are potential reservoirs for HIV-1 came from a study in macaques, in which CD4⁺ T cells were gradually depleted followed infection by a highly pathogenic SIV/HIV-1 chimera (SHIV) strain. In the absence of CD4⁺ T cells, high levels of plasma viral RNA were maintained that was found to originate from tissue macrophages (Igarashi et al. 2001). They also demonstrated that infected macrophages were resistant to a reverse transcriptase inhibitor, as compared to infected CD4⁺ T cells, suggesting that macrophages may persist in the absence of continuous rounds of infection.

Some studies have shown compartmentalization of distinct viral variants in the CNS. For example, HIV-1 infected individuals with symptoms of HIV-associated dementia demonstrated the presence of two distinct HIV-producing cells as seen by the genetically divergent envelope (*env*) sequences associated with experimentally defined phenotypes. In HAD individuals, they observed a rapid decay in T-cell tropic (T-tropic) viruses in the CSF, which correlated with the decay seen in the blood. In contrast, macrophage-tropic (M-tropic) viruses exhibited a slow decay in the CSF after ART initiation, indicating a long-lived reservoir of virus producing cells. Parallel to this study, a model of SIV in macaque also confirmed the presence of compartmentalized SIV variants that evolved independently of viruses found in the periphery, indicating a complete independent evolution and tissue compartmentalization in the brain (Gama et al. 2017). Despite ART, neurological disorders of wide magnitude is found in HIV-1 infected individuals, demonstrating the relevance of HIV-1 infection in resident cells in the CNS (Bhaskaran et al. 2008; Jevtovic et al. 2009).

There have been several studies using humanized mouse models to study HIV-1. In a particular study, macrophages have been shown to harbor HIV-1 RNA and DNA even in mice suppressed by ART (Arainga et al. 2017). In a humanized myeloid only mouse (MoM) model in which human macrophages but not CD4⁺ T cells are reconstituted, replication-competent HIV-1 was found in several tissues, including brain, confirming that, at least in this model, macrophages sustain HIV-1 infection independently of CD4⁺ T-cells (Honeycutt et al. 2016). More recently, the same group took advantage of the MoM model, to evaluate

whether macrophages can also harbor persistent HIV-1 in ART-suppressed MoM. In this study, they showed that HIV-1 could be recovered following treatment interruption. HIV-1 rebounded in approximately 33% of mice at the time of HIV-1 rebound (Honeycutt et al. 2017). The study concluded that in MoM, macrophages were capable of harboring latent HIV-1 and that upon treatment interruption, these cells produced replication competent viruses. While this study is the first to demonstrate a macrophage reservoir in vivo, it is unclear whether the lifespan of macrophages reconstituted in the MoM model were comparable to the lifespan of brain macrophages. In addition, the absence of CD4 T cells limits interpretation of the model and its application to the understanding of HIV-1 infection in humans. Nevertheless, the study provides support to the hypothesis that macrophages serve as a viral reservoir under effective ART.

Macrophages have also been shown to harbor replication competent virus in ART-suppressed macaque (Avalos et al. 2017). In the study, the investigators took advantage of a modified QVOA that was adapted for macrophages, in which brain macrophages were isolated and cultured ex vivo with feeder cells and a mix of molecules such as TNF- α and prostaglandin to promote cell activation. The investigators found that in approximately 87% of ART-suppressed macaques, replication-competent virus was rescued from cultures of macrophages (Avalos et al. 2017).

Establishment of latency in macrophages has also been thought to play a distinct role from CD4⁺ T-cells. Although the mechanisms by which CD4⁺ T-cell establish latency are well known, more investigations are needed to fully understand the mechanism in macrophages. At least for CD4⁺ T-cells, there are two described mechanisms of latency; the first, established in naïve T-cells that carry HIV-1 unintegrated DNA, is the pre-integration complex (Zack et al. 1990). This form of latency is characterized by poor reverse transcriptase activity, which impairs synthesis of proviral DNA (Bukrinsky et al. 1992). However, the clinic relevance of this form of latency is debatable, as naïve T-cells in pre-integration latency are short-lived (Pierson et al. 2002), and therefore may not contribute to long-term HIV-1 persistence. In the contrary, macrophages support unintegrated HIV-1 DNA transcription for long periods of time (Kelly et al. 2008), thus suggesting a role in HIV-1 latency.

The second form of latency, the post-integration of HIV-1 proviral DNA into the host's genome, plays an important role for long-term latency. There are two proposed mechanisms; the first suggests that HIV-1 proviral DNA integrates into heterochromatin region, and therefore is not expressed. The second is the integration into euchromatin regions, which might or might not be expressed. That will depend on many factors, such as the integration site, and the promoters and molecules involved in regulating cellular transcription. The HIV-1 Tat protein plays a crucial role for production of new viral particles. Its functions include interaction with the cellular protein kinase activity TAK (Tat-associated kinase)/P-TEFb (Mancebo et al. 1997, (Zhu et al. 1997), composed of CDK9 and cyclin T1, for its transactivation function (Wei et al. 1998). This step in HIV-1 infection may be different in T-cells and macrophages, and could contribute to distinct mechanisms of latency. TAK/P-TEFb activity is lower in resting CD4⁺ T-cells, which may be limiting HIV-1 replication. Levels of CDK9 and T1 mRNA and protein are increased upon T-cell activation,

consequently inducing TAK/P-TEFb kinase activity, with increased viral replication (Garriga et al. 1998; Herrmann et al. 1998). On the other hand, in circulating monocytes, CDK9 protein levels are elevated (Dong et al. 2009), while cyclin T1 protein levels are close to undetectable. In early-differentiated macrophages, post-transcriptional regulation mechanisms lead to an increase in cyclin T1 protein expression. Later during differentiation, expression of cyclin T1 starts to decrease, leading to a reduction in Tat transactivation (Liou et al. 2004). However, upon inflammatory stimuli, such as LPS, cyclin T1 can be re-induced in macrophages. Altogether, these studies show that latency mechanisms in macrophages may be different from those in CD4+ T-cells, though there may be other factors and pathways contributing to latency in macrophages that are unknown. To achieve a sterile cure, more research is needed to address the mechanisms of latency in cell populations that act as reservoirs.

Conclusions

HIV-1 is a leading cause of morbidity and mortality worldwide. Although ART has dramatically impacted the outlook for individuals living with HIV-1 infection, the majority of infected individuals do not have access to therapy. The use of ART in prevention is also limited and only a fraction of susceptible individuals at risk of infection are on PrEP (King et al. 2014; McMahon et al. 2014). Even in resource-rich countries, lifetime ART is not a solution. Antiretroviral resistance leads to high rates of failure (Fogel et al. 2016; Tsai et al. 2017). Every year, one million individuals die from AIDS-related diseases. Collectively, these facts argue for the development of a cure for infection. Key to this task is a thorough understanding of the viral reservoirs that sustain HIV-1 persistence in the face of suppressive ART. This information would then aid in the design of strategies to eliminate the reservoirs in which the virus persists. Most of the attention has focused on the latent CD4+ T cell. Strategies for elimination of latently infected cells are being explored in the clinic. Those approaches have centered on reactivating the latently infected cell with the hope that renewed viral antigen production would result in clearance of the infected cell by cell-mediated immunity and/or viral cytopathicity. However, those approaches may have limited effectiveness against the macrophage reservoir where the effects of cell mediated immunity and viral cytopathicity are less apparent. Basic questions still need to be answered. Does HIV-1 reside in a latent state in macrophages? If so, what agents might be used to reactivate latent infection of macrophages? What is the longevity of an infected macrophage? Answers to those questions, challenging as they are, would drive a concerted effort to develop approaches for elimination of the macrophage reservoir. It would be better to conduct those studies in concert with studies on the CD4 T+ cell reservoir. Otherwise, we may ultimately discover that removal of the reservoir of CD4+ T cells is not sufficient to cure HIV-1 infection.

Acknowledgments

Funding We acknowledge grant support from National Institute of Health (MH100942, MH093306, AI096109 and AI12065631) to M Stevenson.

References

- Albright AV, Shieh JT, O'Connor MJ, Gonzalez-Scarano F (2000) Characterization of cultured microglia that can be infected by HIV-1. *J Neuro-Oncol* 6(Suppl 1):S53–S60
- Albright AV, Soldan SS, Gonzalez-Scarano F (2003) Pathogenesis of human immunodeficiency virus-induced neurological disease. *J Neuro-Oncol* 9(2):222–227
- Anderson LW, Klevjer-Anderson P, Liggitt HD (1983) Susceptibility of blood-derived monocytes and macrophages to caprine arthritis-encephalitis virus. *Infect Immun* 41(2):837–840 [PubMed: 6307885]
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. *Neurology* 69(18):1789–1799 [PubMed: 17914061]
- Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, Balestra E, Calio R, Perno CF (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. *J Med Virol* 68(4):479–488 [PubMed: 12376954]
- Arainga M, Edagwa B, Mosley RL, Poluektova LY, Gorantla S, Gendelman HE (2017) A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. *Retrovirology* 14(1):17 [PubMed: 28279181]
- Asahchop EL, Meziane O, Mamik MK, Chan WF, Branton WG, Resch L, Gill MJ, Haddad E, Guimond JV, Wainberg MA, Baker GB, Cohen EA, Power C (2017) Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. *Retrovirology* 14(1):47 [PubMed: 29037245]
- Atkins KM, Thomas L, Youker RT, Harriff MJ, Pissani F, You H, Thomas G (2008) HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation: analysis using short interfering RNA and knockout mice. *J Biol Chem* 283(17):11772–11784 [PubMed: 18296443]
- Avalos CR, Abreu CM, Queen SE, Li M, Price S, Shirk EN, Engle EL, Forsyth E, Bullock BT, Mac Gabhann F, Wietgreffe SW, Haase AT, Zink MC, Mankowski JL, Clements JE, Gama L (2017) Brain macrophages in simian immunodeficiency virus-infected, antiretroviral-suppressed macaques: a functional latent reservoir. *MBio* 8(4): e01186–e01117 [PubMed: 28811349]
- Bannert N, Schenten D, Craig S, Sodroski J (2000) The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. *J Virol* 74(23):10984–10993 [PubMed: 11069993]
- Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dautet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 220(4599):868–871 [PubMed: 6189183]
- Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ (2014) Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. *Cell Host Microbe* 16(6):711–721 [PubMed: 25467409]
- Ben Haij N, Planes R, Leghmari K, Serrero M, Delobel P, Izopet J, BenMohamed L, Bahraoui E (2015) HIV-1 tat protein induces production of Proinflammatory cytokines by human dendritic cells and monocytes/macrophages through engagement of TLR4-MD2-CD14 complex and activation of NF-kappaB pathway. *PLoS One* 10(6):e0129425 [PubMed: 26090662]
- Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K, C. Collaboration (2008) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. *Ann Neurol* 63(2):213–221 [PubMed: 17894380]
- Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M (1992) Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. *Proc Natl Acad Sci U S A* 89(14):6580–6584 [PubMed: 1631159]

- Calantone N, Wu F, Klase Z, Deleage C, Perkins M, Matsuda K, Thompson EA, Ortiz AM, Vinton CL, Ourmanov I, Lore K, Douek DC, Estes JD, Hirsch VM, Brenchley JM (2014) Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. *Immunity* 41(3):493–502 [PubMed: 25238099]
- Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. *Nat Med* 15(8):893–900 [PubMed: 19543283]
- Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, Fauci AS (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. *Nat Med* 6(7):757–761 [PubMed: 10888923]
- Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcamí J (2009) Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. *Nat Rev Microbiol* 7(11):798–812 [PubMed: 19834480]
- Cribbs SK, Lennox J, Caliendo AM, Brown LA, Guidot DM (2015) Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. *AIDS Res Hum Retrovir* 31(1):64–70 [PubMed: 25134819]
- Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM (2015) Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. *J Infect Dis* 212(9):1361–1365 [PubMed: 25877550]
- Dikeakos JD, Atkins KM, Thomas L, Emert-Sedlak L, Byeon JJ, Jung J, Ahn J, Wortman MD, Kukull B, Saito M, Koizumi H, Williamson DM, Hiyoshi M, Barklis E, Takiguchi M, Suzu S, Gronenborn AM, Smithgall TE, Thomas G (2010) Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action. *Mol Biol Cell* 21(19):3279–3292 [PubMed: 20702582]
- Dong C, Kwas C, Wu L (2009) Transcriptional restriction of human immunodeficiency virus type 1 gene expression in undifferentiated primary monocytes. *J Virol* 83(8):3518–3527 [PubMed: 19211771]
- Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. *PLoS Pathog* 9(2):e1003174 [PubMed: 23459007]
- Fischer-Smith T, Croul S, Sverstiuk AE, Capini C, L'Heureux D, Regulier EG, Richardson MW, Amini S, Morgello S, Khalili K, Rappaport J (2001) CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. *J Neuro-Oncol* 7(6):528–541
- Fletcher CV, Staskus K, Wietgreffe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proc Natl Acad Sci U S A* 111(6):2307–2312 [PubMed: 24469825]
- Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar-Manning E, Sabin D, McCauley M, Gamble T, Zhang XC, Eron JJ, Gallant JE, Kumwenda J, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim J, Badal-Faesens S, Akelo V, Hosseini-pour MC, Santos BR, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Mayer KH, Chen YQ, Cohen MS, Eshleman SH (2016) Brief report: HIV drug resistance in adults failing early antiretroviral treatment: results from the HIV prevention trials network 052 trial. *J Acquir Immune Defic Syndr* 72(3):304–309 [PubMed: 26859828]
- Gabuzda DH, Ho DD, de la Monte SM, Hirsch MS, Rota TR, Sobel RA (1986) Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. *Ann Neurol* 20(3):289–295 [PubMed: 3532930]
- Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgreffe SW, O'Connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements JE, L.-S. S. Group (2017)

Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. *AIDS* 31(1):5–14 [PubMed: 27898590]

- Garriga J, Peng J, Parreno M, Price DH, Henderson EE, Grana X (1998) Upregulation of cyclin T1/CDK9 complexes during T cell activation. *Oncogene* 17(24):3093–3102 [PubMed: 9872325]
- Gendelman HE, Narayan O, Molineaux S, Clements JE, Ghotbi Z (1985) Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow. *Proc Natl Acad Sci U S A* 82(20):7086–7090 [PubMed: 2996004]
- Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B, Consortium HIVN (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. *AIDS* 25(5):625–633 [PubMed: 21297425]
- Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR (2014) Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. *Ann Intern Med* 161(5):319–327 [PubMed: 25047577]
- Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeier CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG (2017) HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. *PLoS Med* 14(11):e1002417 [PubMed: 29112956]
- Herrmann CH, Carroll RG, Wei P, Jones KA, Rice AP (1998) Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. *J Virol* 72(12):9881–9888 [PubMed: 9811724]
- Honeycutt JB, Wahl A, Baker C, Spagnuolo RA, Foster J, Zakharova O, Wietgreffe S, Caro-Vegas C, Madden V, Sharpe G, Haase AT, Eron JJ, Garcia JV (2016) Macrophages sustain HIV replication in vivo independently of T cells. *J Clin Invest* 126(4):1353–1366 [PubMed: 26950420]
- Honeycutt JB, Thayer WO, Baker CE, Ribeiro RM, Lada SM, Cao Y, Cleary RA, Hudgens MG, Richman DD, Garcia JV (2017) HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. *Nat Med* 23(5):638–643 [PubMed: 28414330]
- Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DI, Keele BF, Ho YC, Siliciano JD, Siliciano RF (2017) Proliferation of latently infected CD4(+) T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. *J Exp Med* 214(4):959–972 [PubMed: 28341641]
- Hufert FT, Schmitz J, Schreiber M, Schmitz H, Racz P, von Laer DD (1993) Human Kupffer cells infected with HIV-1 in vivo. *J Acquir Immune Defic Syndr* 6(7):772–777 [PubMed: 8099611]
- Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N Engl J Med* 360(7):692–698 [PubMed: 19213682]
- Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, Hirsch V, Martin MA (2001) Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. *Proc Natl Acad Sci U S A* 98(2):658–663 [PubMed: 11136236]
- Ioannidis JP, Reichlin S, Skolnik PR (1995) Long-term productive human immunodeficiency virus-1 infection in human infant microglia. *Am J Pathol* 147(5):1200–1206 [PubMed: 7485383]
- Jambo KC, Banda DH, Kankwatira AM, Sukumar N, Allain TJ, Heyderman RS, Russell DG, Mwandumba HC (2014) Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function. *Mucosal Immunol* 7(5):1116–1126 [PubMed: 24472847]
- Jevtovic D, Vanovac V, Veselinovic M, Salemovic D, Ranin J, Stefanova E (2009) The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART. *Biomed Pharmacother* 63(8):561–565 [PubMed: 19026516]

- Kasper MR, Roeth JF, Williams M, Filzen TM, Fleis RI, Collins KL (2005) HIV-1 Nef disrupts antigen presentation early in the secretory pathway. *J Biol Chem* 280(13):12840–12848 [PubMed: 15653685]
- Kelly J, Beddall MH, Yu D, Iyer SR, Marsh JW, Wu Y (2008) Human macrophages support persistent transcription from unintegrated HIV-1 DNA. *Virology* 372(2):300–312 [PubMed: 18054979]
- King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, Little SJ, Smith DM (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE study). *AIDS Behav* 18(9): 1722–1725 [PubMed: 25017425]
- Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. *Science* 233(4768):1089–1093 [PubMed: 3016903]
- Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R (2005) Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. *Virus Res* 111(2): 194–213 [PubMed: 15885841]
- Kumar A, Abbas W, Herbein G (2014) HIV-1 latency in monocytes/ macrophages. *Viruses* 6(4):1837–1860 [PubMed: 24759213]
- Kyei GB, Cheng X, Ramani R, Ratner L (2015) Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. *Cell Host Microbe* 17(1):98–106 [PubMed: 25532805]
- Lenzi GM, Domaol RA, Kim DH, Schinazi RF, Kim B (2015) Mechanistic and kinetic differences between reverse Transcriptases of Vpx coding and non-coding lentiviruses. *J Biol Chem* 290(50): 30078–30086 [PubMed: 26483545]
- Levy RM, Rosenbloom S, Perrett LV (1986) Neuroradiologic findings in AIDS: a review of 200 cases. *AJR Am J Roentgenol* 147(5):977–983 [PubMed: 3490168]
- Li W, Henderson LJ, Major EO, Al-Harhi L (2011) IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner. *J Immunol* 186(12):6771–6778 [PubMed: 21562161]
- Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT (2016) The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. *AIDS* 30(3):343–353 [PubMed: 26588174]
- Lifson JD, Feinberg MB, Reyes GR, Rabin L, Banapour B, Chakrabarti S, Moss B, Wong-Staal F, Steimer KS, Engleman EG (1986) Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. *Nature* 323(6090):725–728 [PubMed: 3095663]
- Liou LY, Herrmann CH, Rice AP (2004) HIV-1 infection and regulation of tat function in macrophages. *Int J Biochem Cell Biol* 36(9):1767–1775 [PubMed: 15183343]
- Maddon PJ, Dalglish AG, McDougal JS, Clapham PR, Weiss RA, Axel R (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell* 47(3): 333–348 [PubMed: 3094962]
- Mamik MK, Banerjee S, Walseth TF, Hirte R, Tang L, Borgmann K, Ghorpade A (2011) HIV-1 and IL-1 β regulate astrocytic CD38 through mitogen-activated protein kinases and nuclear factor-kappaB signaling mechanisms. *J Neuroinflammation* 8:145 [PubMed: 22027397]
- Mancebo HS, Lee G, Flygare J, Tomassini J, Luu P, Zhu Y, Peng J, Blau C, Hazuda D, Price D, Flores O (1997) P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. *Genes Dev* 11(20):2633–2644 [PubMed: 9334326]
- McMahon JM, Myers JE, Kurth AE, Cohen SE, Mannheimer SB, Simmons J, Pouget ER, Tribold N, Haberer JE (2014) Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. *AIDS Patient Care STDs* 28(9):462–474 [PubMed: 25045996]
- Micci L, Alvarez X, Iriele RI, Ortiz AM, Ryan ES, McGary CS, Deleage C, McAtee BB, He T, Apetrei C, Easley K, Pahwa S, Collman RG, Derdeyn CA, Davenport MP, Estes JD, Silvestri G, Lackner AA, Paiardini M (2014) CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. *PLoS Pathog* 10(10):e1004467 [PubMed: 25356757]

- Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RA, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK (2017) A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. *EMBO J* 36(5):604–616 [PubMed: 28122869]
- Moskowitz LB, Hensley GT, Chan JC, Gregorios J, Conley FK (1984) The neuropathology of acquired immune deficiency syndrome. *Arch Pathol Lab Med* 108(11):867–872 [PubMed: 6548362]
- Mosoian A, Zhang L, Hong F, Cunyat F, Rahman A, Bhalla R, Panchal A, Saiman Y, Fiel MI, Florman S, Roayaie S, Schwartz M, Branch A, Stevenson M, Bansal MB (2017) Frontline science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS. *J Leukoc Biol* 101(5):1083–1090 [PubMed: 27986871]
- Narayan O (1983) Role of macrophages in the immunopathogenesis of visna-maedi of sheep. *Prog Brain Res* 59:233–235 [PubMed: 6320268]
- Nguyen LA, Domaal RA, Kennedy EM, Kim DH, Schinazi RF, Kim B (2015) Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template. *Antivir Res* 115:75–82 [PubMed: 25557601]
- Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S (2006) Therapeutic strategies towards HIV-1 infection in macrophages. *Antivir Res* 71(2-3):293–300 [PubMed: 16806514]
- Persidsky Y, Poluektova L (2006) Immune privilege and HIV-1 persistence in the CNS. *Immunol Rev* 213:180–194 [PubMed: 16972904]
- Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M (1997) A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. *J Immunol* 158(7):3499–3510 [PubMed: 9120312]
- Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, Siliciano RF (2002) Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. *J Virol* 76(17):8518–8531 [PubMed: 12163571]
- Rainho JN, Martins MA, Cunyat F, Watkins IT, Watkins DI, Stevenson M (2015) Nef is dispensable for resistance of simian immunodeficiency virus-infected macrophages to CD8+ T cell killing. *J Virol* 89(20):10625–10636 [PubMed: 26269172]
- Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *J Exp Med* 206(6):1273–1289 [PubMed: 19487424]
- Schmitt MP, Steffan AM, Gendault JL, Jaecck D, Royer C, Schweitzer C, Beyer C, Schmitt C, Aubertin AM, Kirn A (1990) Multiplication of human immunodeficiency virus in primary cultures of human Kupffer cells—possible role of liver macrophage infection in the physiopathology of AIDS. *Res Virol* 141(2):143–152 [PubMed: 1693219]
- Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R (2011) HIV-1 replication in the central nervous system occurs in two distinct cell types. *PLoS Pathog* 7(10):e1002286 [PubMed: 22007152]
- Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey M, Stevenson M (2008) Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. *PLoS Pathog* 4(5):e1000057 [PubMed: 18451984]
- Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S, Dandekar S, Clapham PR, Smythies LE, Smith PD (2009) Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. *J Virol* 83(7):3258–3267 [PubMed: 19153236]
- Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. *Nat Med* 9(6):727–728 [PubMed: 12754504]
- Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van

- Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F (2016) Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. *Proc Natl Acad Sci U S A* 113(7): 1883–1888 [PubMed: 26858442]
- Swingler S, Mann AM, Zhou J, Swingler C, Stevenson M (2007) Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. *PLoS Pathog* 3(9):1281–1290 [PubMed: 17907802]
- Tsai HC, Chen IT, Wu KS, Tseng YT, Sy CL, Chen JK, Lee SS, Chen YS (2017) High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014. *Infect Drug Resist* 10:343–352 [PubMed: 29081666]
- Vassena L, Giuliani E, Koppensteiner H, Bolduan S, Schindler M, Doria M (2015) HIV-1 Nef and Vpu interfere with L-selectin (CD62L) cell surface expression to inhibit adhesion and signaling in infected CD4+ T lymphocytes. *J Virol* 89(10):5687–5700 [PubMed: 25822027]
- Vojnov L, Martins MA, Bean AT, Veloso de Santana MG, Sacha JB, Wilson NA, Bonaldo MC, Galler R, Stevenson M, Watkins DI (2012) The majority of freshly sorted simian immunodeficiency virus (SIV)-specific CD8(+) T cells cannot suppress viral replication in SIV-infected macrophages. *J Virol* 86(8):4682–4687 [PubMed: 22318140]
- Wachter C, Eiden LE, Naumann N, Depboylu C, Weihe E (2016) Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy. *J Neuroinflammation* 13(1):272 [PubMed: 27737697]
- Wei P, Garber ME, Fang SM, Fischer WH, Jones KA (1998) A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA. *Cell* 92(4):451–462 [PubMed: 9491887]
- Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB (1986) Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. *Proc Natl Acad Sci U S A* 83(18):7089–7093 [PubMed: 3018755]
- Xing HQ, Moritoyo T, Mori K, Sugimoto C, Ono F, Izumo S (2009) Expression of proinflammatory cytokines and its relationship with virus infection in the brain of macaques inoculated with macrophage-tropic simian immunodeficiency virus. *Neuropathology* 29(1):13–19 [PubMed: 18507770]
- Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS (1990) HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. *Cell* 61(2):213–222 [PubMed: 2331748]
- Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH (1997) Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. *Genes Dev* 11(20):2622–2632 [PubMed: 9334325]

Fig. 1.
HIV-1 crosses the blood brain barrier by a “Trojan horse” mechanism

Fig. 2.
Mechanisms of viral evasion regulated by HIV-1 protein Nef